Corporate Profile

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California.

Presentation

DateTitle
02/28/17
Download Documentation Corporate Presentation February 2017

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
$7.45 + 0.405.67%58,593
Previous CloseToday's OpenIntraday HighIntraday Low
$7.05$7.05$7.50$7.05
Exchange: NASDAQ (US Dollar)
03/23/17 4:00 p.m. ET
Refresh quote

 

Stock chart for: CDTX.O.  Currently trading at $7.45 with a 52 week high of $15.91 and a 52 week low of $6.65.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources